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ABSTRACT
Objectives: Evaluation of the effect of lymphadenectomy in disease-free and overall survival on the low risk corpus cancer.
Material and methods: Between 1994 and 2012, a total of 257 patients with endometrioid type, grade 1 or 2, myometrial 
invasion < 1/2, no intraoperative evidence of macroscopic extrauterine spread was treated surgically. Pelvic lymphadenec-
tomy was performed in 184 cases, and not performed in 73 cases.
Results: There was no difference between two groups about tumor sizes. Also lymphovascular space invasion and histo-
logic grade of two groups were similar. Omission of LA did not worsen DFS and OS in early stage low risk corpus cancer.
Conclusions: Patients who have low risk corpus cancer, can be treated optimally with hysterectomy only.
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INTRODUCTION
   Endometrial cancer is the most common malignancy 
of the female genital tract, in many developed countries [1]. 
10,920 women lost their life because of endometrial cancer, 
in the United States in 2017 [2].
When 80% of patients are caught by a clinician, tumor 
confined to the corpus uteri (stage 1). Five-year survival rate 
of localized cancers 95.5% at the Surveillance Epidemiology 
and End Results (SEER) data [3]. The International Federation 
of Gynecology and Obstetrics (FIGO) recommended in 1988, 
standard staging surgery for endometrial cancer is total 
extrafascial hysterectomy, bilateral salpingo-oophorectomy 
and pelvic-paraaortic lymphadenectomy (PPLA). In 2009, 
last revised surgical staging system for endometrial cancer, 
which includes lymphadenectomy, was reported by the 
FIGO [4, 5]. The American College of Obstetrics and Gy-
necologists (ACOG) recommended to perform systematic 
LA rather than nodal sampling [6].
Hidaka et al, did not suggest systemic LA for low-risk 
corpus cancer (endometrioid type, grade 1 or 2, myome-
trial invasion < 1/2, no intraoperative evidence of macro-
scopic extrauterine spread) because there is no difference 
between DFS and OS [7]. Some retrospective studies have 
recommended that a therapeutic benefit is associated with 
lymphadenectomy (LA) in early-stage endometrial cancer 
[8, 9]. There is a controversy about benefit of PLA in patients 
with early stage endometrial cancer [10, 11].
Objectives
In this study we investigated whether LA was neces-
sary or not in early stage endometrial cancer. The primary 
outcome was to see the role of LA in DFS and OS on low risk 
endometrial cancer patients. The second outcomes were to 
learn demographic specialities, comorbid conditions, pre-op 
Cancer Antigen-125 (CA-125) levels and end-organ metastasis.
MATERIAL AND METHODS
    Two hundred fifty seven patients who were operated 
due to endometrial carcinoma which have endometrioid 
type, FIGO stage 1a, grade 1 or 2 histology at the Izmir 
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Tepecik Research and Teaching Hospital, between 1994 and 
2012, were included in this study. We eliminated patients 
who had preoperative therapy, histologic grade 3, other his-
tologic types and other FIGO stages from the study. Clinical, 
pathological and surgical data were collected. All patients 
were evaluated for OS and DFS. The following clinical data 
were collected from patient medical, surgical, pathological 
reports: demographic characteristics, presenting symptoms, 
serum CA-125 level, date and type of the surgical procedure, 
presence or absence of residual tumor after surgery, number 
of excised and positive lymph nodes, presence or absence of 
ascites, tumor pathological characteristics (grade and size), 
date of recurrence, treatment after recurrence, date of the 
last medical examination and date of death. 
Primarily cases were divided into two groups, under-
went lymph node dissection (LND) and non-lymph node 
dissection (non-LND). The patients were classified as 
‘non-Lymph node dissection’ if only a total hysterectomy 
with unilateral or bilateral salpingo-oophorectomy with 
or without omentectomy was performed. Complete stag-
ing was defined as pelvic washing, omentectomy, bilateral 
pelvic and para-aortic lymph node dissection with bilateral 
salpingo-oophorectomy and total abdominal hysterectomy. 
Patients who underwent complete staging were defined 
as ‘Lymph node dissection’. 184 patients underwent lymph 
node dissection, and 73 patients did not. The decision 
whether or not to perform lymph node dissection was made 
according to the results of intraoperative pelvic examination 
findings and frozen section results.
The patients returned for a follow-up every three months 
for the first 2 years, every 6 months for the next 3 years, and 
annually, thereafter. Computed tomography or magnetic 
resonance imaging was performed annually. The revised 
2009 FIGO staging system was used. All groups analyzed 
demographic data, survival periods, recurrence and me-
tastasis. Comorbid conditions, pre-op CA-125 levels, tumor 
diameters were other findings.
The survival analysis was based on the Kaplan-Meier 
method, and the results were compared using the log-rank 
test. DFS was defined as the time from the date of the pri-
mary surgery to detection of recurrence or the latest obser-
vation. OS was defined as the time from the date of primary 
surgery to death or the latest observation. The chi-square 
test and Student’s t test for unpaired data were used for 
statistical analyses. Cox regression analysis was used to 
determine factors affecting the survival, and the results 
are presented as Hazard Ratios (HRs), with 95% Confidence 
İntervals (CIs). All statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS ver.11.5). 
The p-value of < 0.05 was considered as statistically sig-
nificant.
RESULTS
Ninety eight patients underwent PLA, 86 patients under-
went PPLA in this study. There was no lymph node spreading 
and positive peritoneal cytology at LND group.
The age range in the LND group was 34–77 (mean age, 
53.9 ± 7.9 years), whereas in the non-LND group was 40– 
–74 (mean age, 54.8 ± 7.4 years). Comorbid disease had seen 
much more at non-LND cases, than LND cases (p < 0.05). 
Demographic data is summarized in Table 1.
When the postoperative pathology specimens of two 
groups had been analyzed, we saw there were no difference 
about primary tumor diameter. Also there were no differ-
ence about histologic grade and LVSI ratio. Preoperative 
CA-125 levels of cases at non-LND group less than LND 
Table 1. Demographic findings
Not undergone lymphadenectomy 
(n = 73) mean ± SD
n — %
Undergone lymphadenectomy 
(n = 184) mean ± SD
n — %
p
Age 54.8 ± 7.4 53.9 ± 7.9 0.391
First menstruation age 13.3 ± 1.1 13.1 ± 1.0 0.149
Last menstruation age* 48.7 ± 3.5 (n: 51) 48.5 ± 4.0 (n: 136) 0.820
Parity 2.7 ± 1.1 3.0 ± 1.5 0.338
Menopause
no 22 (% 30.1) 48 (% 26.1)
yes 51 (% 69.9) 136 (% 73.9)
Comorbid disease
no 33 (% 45.2) 109 (% 59.2)
0.041
yes 40 (% 54.8) 75 (% 40.8)
HT 22 (% 30.1) 38 (% 20.6)
DM 6 (% 8.2) 14 (% 7.6)
HT + DM 11 (% 15) (% 9.7)
* — Mean age of cases at menopause; DM — Diabetes Mellitus; HT — Hypertension
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group (p < 0.05). Level range of preoperative CA-125 levels 
in non-LND and LND group were 3–64 U/mL, 2–410 U/mL, 
respectively. Clinicopathological characteristics of the pa-
tients are summarized in Table 2.
Eight cases had end-organ metastasis at LND group, 
2 cases had lung metastasis (postoperative 40th and 60th 
month), 2 cases had liver metastasis (postoperative 8th and 
17th month), 1 case had colon metastasis (postoperative 
48th month), 1 case had bone metastasis (postoperative 
7th month), 1 case had rectum metastasis (postoperative 
84th month), 1 case had paracolic peritoneal metastasis 
(postoperative 9th month). One patient had liver metastasis 
(postoperative 30th month) at non- LND group.
Two patients died at LND group, the first one, who had 
bone metastasis, died at postoperative 12th month, second 
patient died in the 21st month who had liver metastasis at 
postoperative 17th month. There was no local recurrence 
both of two groups, and no difference about metastasis and 
exitus statistics. Also we did not see any statistical difference 
between two groups about DFS and OS.
Metastatic and non-metastatic patients in LND group 
analyzed at Table 3. There were no statistical differences 
about tumor diameter, LVSI and CA-125 levels between 
metastatic and non-metastatic patients (p > 0.05). At meta-
static group, histologic grade and exitus rate were upper 
than non-metastatic group (p < 0.05).
DISCUSSION
FIGO recommended a systemic surgical staging 
system for corpus cancer, in 1988 [12]. After this rec-
ommendation, controversy has become the role of 
the addition of LA to surgical procedures [13]. Multi-
ple retrospective studies have shown that a low-risk 
endometrial cancer patients had a small overall risk of lymph 
node involvement [14–16]. In our study, LVSI rate was 2.7% 
at non-LND group, and 2.2% at LND group. Also there was 
no lymph node spreading, both two study groups.  
Trimble et al. demonstrated that the 5-year relative sur-
vival for 6363 women with stage I endometrial cancer who 
did not undergo lymph node sampling was 98%, compared 
to 96% for 2831 women who underwent lymph node sam-
pling. It means that lymph node sampling did not appear to 
convey survival benefit [17]. When we analyzed our cases, 
DFS was 88.8 ± 43.2 months, OS was 91.0 ± 43.5 months in 
LND group. On the other hand, DFS was 97.9 ± 48.7 months, 
OS was 98.8 ± 48.1 months in non-LND group. There were no 
Table 2. Preoperative CA-125 levels and tumor diameters, histologic characteristics at postoperative specimens
Not undergone lymphadenectomy 
(n = 73) mean ± SD
n — %
Undergone lymphadenectomy 
(n = 184) mean ± SD
N — %
p
Tumor diameter          2.45 ± 1.68 cm        2.37 ± 1.38 cm 0.846
CA-125 level 10.9 ± 9.0 15.6 ± 31.2 0.025
LVSI
no 71 (% 97.3) 180 (% 97.8)
1,000
yes 2 (% 2.7) 4 (% 2.2)
Histologic grade
1 51 (% 69.9) 125 (% 67.9)
0.764
2 22 (% 30.1) 59 (% 32.1)
Metastasis 1 (% 1.4) 8 (% 4.3) 0.242
Exitus 0 (% 0) 2 (% 1.1) 1,000
Table 3. CA-125 levels, tumor diameters, histologic grades and exitus numbers of undergone lymphadenectomy patients
Undergone lymphadenectomy 
patients (n = 184)
Non-Metastatic patients
Ort. ± S.S./n — %
Metastatic patients
Ort. ± S.S./n —% p
Tumor diameter        2.36 ± 1.39 cm      2.38 ± 1.22 cm 0.940
CA-125 level 13.3 ± 10.9 66.5 ± 139.2 0.075
Exitus
no 176 (% 100) 6 (% 75)
0.002
yes 0 (% 0 ) 2 (% 25)
LVSI
no 172 (% 97.7) 8 (% 100)
1,000
yes 4 (% 2.3) 0 (% 0)
Histologic grade
1 123 (% 69.9) 2 (% 25)
0.008
2 53 (% 30.1) 6 (% 75)
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significant differences between two groups about survival, 
as shown in Figure 1 (p = 0.828).
Schink et al. presented a 4% risk of lymph node involve-
ment when tumor size was < 2 cm, compared with 15% if 
tumors were > 2 cm [18]. Primary tumor diameter has been 
described as a predictor of lymph node invasion in endome-
trial cancer [19]. Mariani et al. indicated that a low-risk group 
could be defined as patients with: (i) endometrioid subtype; 
(ii) myometrial invasion of 50% or less; (iii) histological grade 
1–2 and (iv) no intraoperative evidence of macroscopic 
disease. In 2004, they revised the criteria (Mayo criteria) and 
tumor size (diameter of ≤ 2 cm) was newly introduced [20]. 
In this study, mean tumor sizes were 2.37 cm and 2.45 cm in 
the LND group and non-LND group, respectively. This find-
ing, was different from literature. The importance of tumor 
size about lymph node spreading, should be confirmed in 
future prospective large-scale randomized clinical trials in 
the low risk corpus cancer.
Most of the endometrium cancer patients have comor-
bid diseases such as obesity, diabetes mellitus, hyperten-
sion and metabolic syndrome [21]. In the present study, 
most common comorbid diseases were hypertension and 
diabetes mellitus, as shown in Table 1. 
There were no statistical difference, about end-or-
gan metastasis between two groups (p = 0.242). We have 
not seen any vaginal recurrence in this study.
Different preoperative predictor types were studied to 
detect lymph node involvement to prevent unnecessary 
lymph node dissection. CA 125 and different imaging mo-
dalities were found as useful predictors for more advanced 
disease [22]. MRI data and serum CA-125 levels were used 
at the preoperative screening of lymph node metastasis in 
low risk endometrial cancer. Serum CA-125 levels greater 
than 35 U/mL is a risk factor [23]. In this study, interval of 
preoperative CA-125 levels 3–64 U/mL at non-LND group, 
2–410 U/mL at LND group. When we analyzed Table 3, 
preoperative CA-125 levels upper than 35 U/mL at meta-
static patients, and less than 35 U/mL at non-metastatic 
patients. Therefore, the possibility of end-organ metastasis 
increases in patients with high pre-operative CA-125 values, 
making lymphadenectomy seem reasonable. If lymphad-
enectomy is performed, CA-125 and other risk factors must 
be considered.
This study has several limitations. First of all, this is 
a cross-sectional study with a small sample size. Secondly, 
it is a retrospective study. The third disadvantage was that 
surgeries performed by different surgeons.
CONCLUSIONS
       As shown in this study, women with low risk endo-
metrial cancer, as defined by the Mayo criteria, have a low 
rate of lymph node metastasis. Also, there was no survival 
benefit of LA in DFS and OS on low risk endometrial cancer 
patients, same with literature (p = 0.828). This results should 
be confirmed in future, prospective large-scale randomized 
clinical trials.
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